<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79034">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035046</url>
  </required_header>
  <id_info>
    <org_study_id>P120111</org_study_id>
    <nct_id>NCT02035046</nct_id>
  </id_info>
  <brief_title>Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter</brief_title>
  <acronym>HEPHYGI</acronym>
  <official_title>Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gitelman syndrome is a salt wasting tubulopathy caused by mutations in the SLC12A3 gene
      coding for the thiazide sensitive sodium chloride cotransporter. This disease mimics the
      chronic treatment with thiazide diuretics and is characterized by renal hypokalemia, low to
      normal blood pressure, hypocalciuria and hypomagnesemia. The purpose of this study is to
      determine whether the heterozygous carriers present the metabolic risks and/or the benefits
      of this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gitelman syndrome (GS), is an autosomal recessive salt wasting tubulopathy caused mainly by
      loss of function mutations in the SLC12A3 gene coding for the thiazide sensitive
      sodium-chloride cotransporter (NCC). Thus, GS mimics a chronic treatment with high doses of
      thiazide diuretics. NCC is expressed in the distal convoluted tubule, which is responsible
      for 7% of sodium chloride reabsorption.  GS is the more frequent hereditary tubulopathy with
      estimated prevalence of 1/40000, which implicates that 1% of general population are
      heterozygous carriers (600 000 in France). Previous publications suggest that the apparently
      asymptomatic heterozygous carriers could present some clinical traits of GS or chronic
      thiazide treatment. These including: beneficial aspects (low blood pressure, low urinary
      calcium excretions) or metabolic risks (hypokalemia, insulin resistance). Nevertheless,
      these studies do not evaluate all the aspects and blood pressure was evaluated once in
      hospital setting.   This study aims to compare home monitoring blood pressure; salt balance;
      potassium, glucose lipid and mineral metabolism and vascular function in 100 heterozygous
      carriers, 50 GS patients and 100 controls persons (without mutations in SLC12A3 gene).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Systolic blood pressure evaluated by self-measurement</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>self-measurement at home, 3 times a day during 3 consecutive days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salt balance</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood renin and aldosterone measurements, 24h urinary sodium and aldosterone excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium metabolism</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dietary intake, blood potassium and 24 h urinary potassium excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipide metabolism</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>BMI, blood cholesterol, LDL, HDL and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose, insulin, HOMA index, pre and post test</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral metabolism</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood and urinary calcium, magnesium and phosphate. PTH, 25 OH vitamin D calcitriol, bone remodeling markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated GFR, proteinuria and albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function evaluation</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pulse wave velocity and central blood pressure. Blood and urinary vascular function markers</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heterozygous Carriers of Gitelman Syndrome</condition>
  <arm_group>
    <arm_group_label>controls persons</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>controls persons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GS patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heterozygous carriers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>heterozygous carriers</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>controls persons</arm_group_label>
    <arm_group_label>GS patients</arm_group_label>
    <arm_group_label>heterozygous carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine sample</intervention_name>
    <arm_group_label>controls persons</arm_group_label>
    <arm_group_label>GS patients</arm_group_label>
    <arm_group_label>heterozygous carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood pressure</intervention_name>
    <arm_group_label>controls persons</arm_group_label>
    <arm_group_label>GS patients</arm_group_label>
    <arm_group_label>heterozygous carriers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gitelman syndrome patients, relatives carrying heterozygous mutations and relatives
             or healthy voluntaries without mutations.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Vargas-Poussou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departement of Genetics. Assistance Publique Hôpitaux de Paris,Hôpital Européen Georges Pompidou.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Blanchard, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Center. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou. Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Essig, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Departement of Nephrology. Centre Hospitalier Universitaire. Limoges, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Philippe Haymann, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Functional Investigations. Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Tack, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Functional Investigations. Centre Hospitalier Universitaire, Hôpital de Rangueil. Toulouse, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence DUBOURG, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Functional Investigations. Hospices Civils de Lyon, Hôpital Edouard Herriot. Lyon, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Department. Centre Hospitalier Universitaire, Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042 Limoges cedex</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Essig, MD, PhD</last_name>
      <phone>+33 (0)5 55 05 64 51</phone>
      <email>marie.essig@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien Allard, MD</last_name>
      <email>Julien.Allard@chu-limoges.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Functional Investigations. Hospices Civils de Lyon, Hôpital Edouard Herriot.</name>
      <address>
        <city>Lyon</city>
        <zip>69437 Lyon</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Dubourg, MD, PhD</last_name>
      <phone>+33 (0)4 72 11 02 44</phone>
      <email>laurence.dubourg@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou.</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Blanchard, MD, PhD</last_name>
      <phone>+33 (0)1 56 09 29 13</phone>
      <email>anne.balanchard@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Functional Investigations. Assistance Publique Hôpitaux de Paris, Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Philippe Haymann, MD, PhD</last_name>
      <phone>+33 (0)1 56 01 67 74</phone>
      <email>jean-philippe.haymann@tnn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Functional Investigations. Centre Hospitalier Universitaire, Hôpital de Rangueil.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 TOULOUSE cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan Tack, MD, PhD</last_name>
      <phone>+ 33 (0)5 61 32 26 83</phone>
      <email>tack.i@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion Vallet, MD, PhD</last_name>
      <phone>+ 33 (0)5 61 32 26 83</phone>
      <email>vallet.m@chu-toulouse.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cruz DN, Simon DB, Nelson-Williams C, Farhi A, Finberg K, Burleson L, Gill JR, Lifton RP. Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension. 2001 Jun;37(6):1458-64.</citation>
    <PMID>11408395</PMID>
  </reference>
  <reference>
    <citation>Tago N, Kokubo Y, Inamoto N, Naraba H, Tomoike H, Iwai N. A high prevalence of Gitelman's syndrome mutations in Japanese. Hypertens Res. 2004 May;27(5):327-31.</citation>
    <PMID>15198479</PMID>
  </reference>
  <reference>
    <citation>Fava C, Montagnana M, Rosberg L, Burri P, Almgren P, Jönsson A, Wanby P, Lippi G, Minuz P, Hulthèn LU, Aurell M, Melander O. Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure. Hum Mol Genet. 2008 Feb 1;17(3):413-8. Epub 2007 Nov 1.</citation>
    <PMID>17981812</PMID>
  </reference>
  <reference>
    <citation>Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008 May;40(5):592-9. doi: 10.1038/ng.118. Epub 2008 Apr 6.</citation>
    <PMID>18391953</PMID>
  </reference>
  <reference>
    <citation>Hsu YJ, Yang SS, Chu NF, Sytwu HK, Cheng CJ, Lin SH. Heterozygous mutations of the sodium chloride cotransporter in Chinese children: prevalence and association with blood pressure. Nephrol Dial Transplant. 2009 Apr;24(4):1170-5. doi: 10.1093/ndt/gfn619. Epub 2008 Nov 25.</citation>
    <PMID>19033254</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gitelman</keyword>
  <keyword>Heterozygous SLC12A3 mutation</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Hypokalemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gitelman Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
